Question · asked by 1 review
Aciclovir (oral or intravenous) for treatment vs placebo: Duration of viral shedding
- Population
- Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
- Intervention
- Aciclovir (oral or intravenous) for treatment
- Comparison
- placebo
- Outcome
- Duration of viral shedding
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Aciclovir (oral or intravenous) for treatment vs Placebo Duration of viral shedding · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients /… Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer (2009) · Cochrane All outcomes | Two studies. Statistically significant difference in median duration of virus shedding in favour of intravenous aciclovir (2.5 days versus 17.0 days, P = 0.0002; Meyers 1982) and oral aciclovir (2 days versus more than… | 2 studies | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes | 2008-11 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.